Article Text

Download PDFPDF
Pyrogenic lower limbs
  1. Eurydice Angeli1,2,3,
  2. Alexander Ariel Padrón González1,
  3. Diaddin Hamdan1,4,
  4. Gabriel Pop5,
  5. Géraldine Falgarone1,3,6,
  6. Guilhem Bousquet1,2,3
  1. 1INSERM, UMR_S942 MASCOT, F-75006, Paris, France
  2. 2AP-HP, Hôpital Avicenne, Oncologie médicale, F-93000, Bobigny, France
  3. 3Unviersité Sorbonne Paris Nord, F-93017, Bobigny, France
  4. 4Hôpital La Porte Verte, F-78000, Versailles, France
  5. 5Département de médecine nucléaire, hôpital Avicenne, AP-HP, F-93009, Bobigny, France
  6. 6Unité de Médecine Ambulatoire (UMA), hôpital Avicenne, AP-HP, F-93009, Bobigny, France
  1. Correspondence to Professor Géraldine Falgarone, AP-HP, Unité de Médecine Ambulatoire (UMA), hôpital Avicenne, F-93009, Bobigny, Île-de-France, France; g.falgarone{at}aphp.fr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In 2020, a 45-year-old woman underwent a right nephrectomy for a localised clear-cell renal cell carcinoma. A year later, she experienced a febrile metastatic relapse with a large 15 cm thoracic para-aortic mass and a pleural effusion. An exhaustive investigation concluded to a febrile state linked to tumour progression. The patient was treated with a combination of nivolumab (anti PD-1; 3 mg/kg every 3 weeks) and ipilimumab (anti CTLA-4; 1 mg/kg every 3 weeks) associated with oral prednisone at 20 mg/day to treat the fever. After 3 months of treatment, she experienced a good clinical response, and the fever disappeared. Partial response was observed on CT imaging, after which prednisone was discontinued.

One month later, the fever reappeared, associated with …

View Full Text

Footnotes

  • Handling editor Josef S Smolen

  • Twitter @FalgaGe

  • Contributors Planning: EA, GF and GB. Conducting: EA, AAPG, DH, GP, GF and GB. Reporting: EA, GF and GB.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.